Prior corticosteroid use by steroid-refractory status
| . | GVHD progression after 3 d* (n = 19) . | No improvement in GVHD after 7 d* (n = 30) . | New GVHD† (n = 8) . | Taper intolerant (n = 14) . | Total (N = 71) . |
|---|---|---|---|---|---|
| Dose of corticosteroid at enrollment, mg/d | |||||
| Mean (SD) | 179.9 (58.1) | 169.9 (63.5) | 114.2 (55.0) | 124.1 (45.9) | 157.3 (62.2) |
| Median (range) | 180.0 (81.3-300.0) | 168.8 (62.5-300.0) | 109.4 (50.0-212.5) | 125.0 (60.0-200.0) | 156.3 (50.0-300.0) |
| Days on corticosteroids before enrollment | |||||
| Mean (SD) | 31.6 (52.8) | 32.2 (54.9) | 20.6 (23.5) | 28.9 (23.4) | 30.1 (46.2) |
| Median (range) | 14.0 (6.0-224.0) | 13.0 (6.0-285.0) | 13.5 (3.0-75.0) | 21.0 (6.0-85.0) | 15.0 (3.0-285.0) |
| . | GVHD progression after 3 d* (n = 19) . | No improvement in GVHD after 7 d* (n = 30) . | New GVHD† (n = 8) . | Taper intolerant (n = 14) . | Total (N = 71) . |
|---|---|---|---|---|---|
| Dose of corticosteroid at enrollment, mg/d | |||||
| Mean (SD) | 179.9 (58.1) | 169.9 (63.5) | 114.2 (55.0) | 124.1 (45.9) | 157.3 (62.2) |
| Median (range) | 180.0 (81.3-300.0) | 168.8 (62.5-300.0) | 109.4 (50.0-212.5) | 125.0 (60.0-200.0) | 156.3 (50.0-300.0) |
| Days on corticosteroids before enrollment | |||||
| Mean (SD) | 31.6 (52.8) | 32.2 (54.9) | 20.6 (23.5) | 28.9 (23.4) | 30.1 (46.2) |
| Median (range) | 14.0 (6.0-224.0) | 13.0 (6.0-285.0) | 13.5 (3.0-75.0) | 21.0 (6.0-85.0) | 15.0 (3.0-285.0) |